Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Improved Transparency In Europe: TTIP And Trade Secrets Legislation Could Hold Back Progress In 2015

Executive Summary

Castigated for not providing public access to clinical trial data nor details of a proposed free trade deal with the U.S., the European Commission and national regulatory agencies will push transparency this year. But pending legislation on trade secrets, data protection and trademarks could hold back progress in this arena.

You may also be interested in...



EMA Leadership Goes To Pott After Rasi Retroactively Unhired

Andreas Pott, who helped steer agency through Mediator scandal, becomes acting director again as irregularities in 2011’s recruitment process force departure of Guido Rasi – who himself might still get top job again once hiring process reboots.

MEPs Pass Clinical Trials Laws But Implementation Will Be Troublesome

Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel